[{"id":"e9087e98-84d9-4794-8123-a03a7c489eac","acronym":"CHAARTED2","url":"https://clinicaltrials.gov/study/NCT03419234","created_at":"2025-02-25T17:35:55.932Z","updated_at":"2025-02-25T17:35:55.932Z","phase":"Phase 2","brief_title":"Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel","source_id_and_acronym":"NCT03419234 - CHAARTED2","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 223","initiation":"Initiation: 04/26/2018","start_date":" 04/26/2018","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2025-01-29"},{"id":"9eb44888-36d6-498e-87f2-66cdcbe3ea1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02099864","created_at":"2021-01-17T17:57:53.255Z","updated_at":"2025-02-25T15:33:07.009Z","phase":"Phase 2","brief_title":"Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy","source_id_and_acronym":"NCT02099864","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • PTEN • AR • RB1","pipe":" | ","alterations":" PTEN mutation • AR splice variant 7","tags":["TP53 • PTEN • AR • RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/05/2014","start_date":" 02/05/2014","primary_txt":" Primary completion: 10/01/2019","primary_completion_date":" 10/01/2019","study_txt":" Completion: 07/08/2024","study_completion_date":" 07/08/2024","last_update_posted":"2024-09-19"},{"id":"a582d818-66bf-4d29-99ae-6395bae8c930","acronym":"","url":"https://clinicaltrials.gov/study/NCT03700099","created_at":"2021-01-18T18:08:05.718Z","updated_at":"2025-02-25T15:25:55.463Z","phase":"Phase 2","brief_title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Treatment With Docetaxel Followed by Enzalutamide","source_id_and_acronym":"NCT03700099","lead_sponsor":"Instituto do Cancer do Estado de São Paulo","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • Xtandi (enzalutamide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/03/2019","start_date":" 09/03/2019","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-04-15"},{"id":"7143627d-c8e8-461b-94ec-fbc84af3d151","acronym":"URODETECT-WP1","url":"https://clinicaltrials.gov/study/NCT05453604","created_at":"2022-07-12T10:54:37.868Z","updated_at":"2024-07-02T16:35:29.461Z","phase":"","brief_title":"Evaluation Protocols for Isolation of Analytes From Urine for Future Oncology Applications","source_id_and_acronym":"NCT05453604 - URODETECT-WP1","lead_sponsor":"Novosanis NV","biomarkers":" HER-2 • PIK3CA • AR • ERG • TMPRSS2","pipe":" | ","alterations":" AR splice variant 7","tags":["HER-2 • PIK3CA • AR • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 105","initiation":"Initiation: 06/18/2020","start_date":" 06/18/2020","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-11-13"},{"id":"c6e6c882-acce-439b-98fd-2069d69504e3","acronym":"URODETECT-WP2","url":"https://clinicaltrials.gov/study/NCT05454371","created_at":"2022-07-12T10:54:47.254Z","updated_at":"2024-07-02T16:35:29.484Z","phase":"","brief_title":"Investigation of Urinary Biomarkers for the Detection of Prostate Cancer","source_id_and_acronym":"NCT05454371 - URODETECT-WP2","lead_sponsor":"Novosanis NV","biomarkers":" AR • ERG • TMPRSS2","pipe":" | ","alterations":" AR splice variant 7","tags":["AR • ERG • TMPRSS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 12/01/2023","start_date":" 12/01/2023","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-11-13"},{"id":"0d7ff3cc-6422-42b2-8b6f-d9a6554297bf","acronym":"","url":"https://clinicaltrials.gov/study/NCT03123978","created_at":"2021-07-07T15:54:06.603Z","updated_at":"2024-07-02T16:35:49.518Z","phase":"Phase 1","brief_title":"Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancer","source_id_and_acronym":"NCT03123978","lead_sponsor":"Mamta Parikh","biomarkers":" AR","pipe":" | ","alterations":" AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • niclosamide"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 01/09/2017","start_date":" 01/09/2017","primary_txt":" Primary completion: 01/14/2022","primary_completion_date":" 01/14/2022","study_txt":" Completion: 04/19/2022","study_completion_date":" 04/19/2022","last_update_posted":"2023-04-26"},{"id":"25d30b28-b610-4c83-bcfc-f5e13ee3ac85","acronym":"","url":"https://clinicaltrials.gov/study/NCT04742972","created_at":"2021-07-05T17:34:50.356Z","updated_at":"2024-07-02T16:35:59.352Z","phase":"","brief_title":"Prostate PMSABR Study","source_id_and_acronym":"NCT04742972","lead_sponsor":"Darren Poon","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2021","start_date":" 02/25/2021","primary_txt":" Primary completion: 09/15/2022","primary_completion_date":" 09/15/2022","study_txt":" Completion: 09/16/2022","study_completion_date":" 09/16/2022","last_update_posted":"2022-12-09"},{"id":"a436e6fd-356f-49de-8a27-97d65692d9e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03236688","created_at":"2021-07-07T15:54:07.425Z","updated_at":"2024-07-02T16:36:02.923Z","phase":"","brief_title":"Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)","source_id_and_acronym":"NCT03236688","lead_sponsor":"Exosome Diagnostics, Inc.","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7 • AR splice variant 7 negative","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7 • AR splice variant 7 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Suspended","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-10-06"},{"id":"4f6d93b4-be3f-49d8-99d0-e1e8eb726d81","acronym":"PSMA-BAT","url":"https://clinicaltrials.gov/study/NCT04424654","created_at":"2021-07-05T17:30:35.370Z","updated_at":"2024-07-02T16:36:06.125Z","phase":"Phase 2","brief_title":"Biomarker Analysis of Castration-resistant Prostate Cancer Undergoing Bipolar Androgen Therapy","source_id_and_acronym":"NCT04424654 - PSMA-BAT","lead_sponsor":"Hospital Sirio-Libanes","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 09/22/2020","start_date":" 09/22/2020","primary_txt":" Primary completion: 05/01/2022","primary_completion_date":" 05/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2022-08-03"},{"id":"848d9860-9717-4776-91f6-1c9e7b96754b","acronym":"STARVE-PC","url":"https://clinicaltrials.gov/study/NCT02601014","created_at":"2021-01-17T17:56:17.908Z","updated_at":"2025-02-25T14:35:59.064Z","phase":"Phase 2","brief_title":"Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7","source_id_and_acronym":"NCT02601014 - STARVE-PC","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Xtandi (enzalutamide)"],"overall_status":"Completed","enrollment":" Enrollment 32","initiation":"Initiation: 03/15/2016","start_date":" 03/15/2016","primary_txt":" Primary completion: 12/03/2020","primary_completion_date":" 12/03/2020","study_txt":" Completion: 10/06/2021","study_completion_date":" 10/06/2021","last_update_posted":"2022-02-03"},{"id":"098d33f4-6759-4d74-9fca-b364e3f3f2d4","acronym":"PRORADIUM","url":"https://clinicaltrials.gov/study/NCT02925702","created_at":"2021-10-27T06:44:55.098Z","updated_at":"2024-07-02T16:36:50.907Z","phase":"","brief_title":"PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.","source_id_and_acronym":"NCT02925702 - PRORADIUM","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" AR","pipe":" | ","alterations":" AR amplification • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xofigo (radium Ra-223 dichloride)"],"overall_status":"Unknown status","enrollment":" Enrollment 161","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 01/01/2019","primary_completion_date":" 01/01/2019","study_txt":" Completion: 09/01/2020","study_completion_date":" 09/01/2020","last_update_posted":"2020-01-27"},{"id":"d865a9f7-2178-4ced-881c-a75158e29a4f","acronym":"PROSENZA","url":"https://clinicaltrials.gov/study/NCT02922218","created_at":"2021-01-18T14:20:52.861Z","updated_at":"2024-07-02T16:36:50.930Z","phase":"","brief_title":"PROSENZA: Prospective Multi-Centre Study of Prognostic Factors in mCRPC Patients Treated With Enzalutamide.","source_id_and_acronym":"NCT02922218 - PROSENZA","lead_sponsor":"Centro Nacional de Investigaciones Oncologicas CARLOS III","biomarkers":" PTEN • AR • ERG","pipe":" | ","alterations":" AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression","tags":["PTEN • AR • ERG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR amplification • AR splice variant 7 • AR-V7 expression • AR splice variant 7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide)"],"overall_status":"Unknown status","enrollment":" Enrollment 187","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 01/01/2020","primary_completion_date":" 01/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2020-01-27"},{"id":"86014f68-4a3e-49b8-af42-63a4717724a7","acronym":"BARRIER-P","url":"https://clinicaltrials.gov/study/NCT02429193","created_at":"2021-01-18T11:37:20.503Z","updated_at":"2024-07-02T16:36:51.426Z","phase":"Phase 2","brief_title":"Biomarkers of Androgen Response and Resistance In Evolution During a Rising PSA","source_id_and_acronym":"NCT02429193 - BARRIER-P","lead_sponsor":"University Health Network, Toronto","biomarkers":" AR","pipe":" | ","alterations":" AR mutation • AR expression • AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR mutation • AR expression • AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • abiraterone acetate • prednisone"],"overall_status":"Completed","enrollment":" Enrollment 16","initiation":"Initiation: 03/01/2016","start_date":" 03/01/2016","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 09/01/2019","study_completion_date":" 09/01/2019","last_update_posted":"2020-01-13"},{"id":"b31dc54e-2efd-4c43-8360-7be499178a49","acronym":"PRIMERA","url":"https://clinicaltrials.gov/study/NCT04188275","created_at":"2021-07-07T15:54:23.008Z","updated_at":"2024-07-02T16:36:52.874Z","phase":"","brief_title":"CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION","source_id_and_acronym":"NCT04188275 - PRIMERA","lead_sponsor":"Azienda Ospedaliero-Universitaria Careggi","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate"],"overall_status":"Unknown status","enrollment":" Enrollment 46","initiation":"Initiation: 12/01/2018","start_date":" 12/01/2018","primary_txt":" Primary completion: 06/30/2020","primary_completion_date":" 06/30/2020","study_txt":" Completion: 06/30/2022","study_completion_date":" 06/30/2022","last_update_posted":"2019-12-05"},{"id":"41e57239-1225-4568-8192-be2ab872b81f","acronym":"PROPHECY","url":"https://clinicaltrials.gov/study/NCT02269982","created_at":"2021-01-17T17:57:56.919Z","updated_at":"2024-07-02T16:36:58.997Z","phase":"","brief_title":"Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY","source_id_and_acronym":"NCT02269982 - PROPHECY","lead_sponsor":"Duke University","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"],"overall_status":"Completed","enrollment":" Enrollment 120","initiation":"Initiation: 05/14/2015","start_date":" 05/14/2015","primary_txt":" Primary completion: 09/01/2017","primary_completion_date":" 09/01/2017","study_txt":" Completion: 04/30/2019","study_completion_date":" 04/30/2019","last_update_posted":"2019-06-10"},{"id":"767c3252-70b0-43a5-8f16-55162b11e9d9","acronym":"CABACARE","url":"https://clinicaltrials.gov/study/NCT03356912","created_at":"2021-01-18T16:34:15.578Z","updated_at":"2024-07-02T16:37:15.509Z","phase":"Phase 2","brief_title":"CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy","source_id_and_acronym":"NCT03356912 - CABACARE","lead_sponsor":"Consorzio Oncotech","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e docetaxel • abiraterone acetate • prednisone • cabazitaxel"],"overall_status":"Unknown status","enrollment":" Enrollment 220","initiation":"Initiation: 11/22/2017","start_date":" 11/22/2017","primary_txt":" Primary completion: 05/04/2021","primary_completion_date":" 05/04/2021","study_txt":" Completion: 05/04/2021","study_completion_date":" 05/04/2021","last_update_posted":"2017-12-14"},{"id":"4a5ef320-f912-4490-8737-c7482457db3c","acronym":"CARVE","url":"https://clinicaltrials.gov/study/NCT02621190","created_at":"2021-07-07T15:53:53.162Z","updated_at":"2024-07-02T16:37:29.724Z","phase":"Phase 2","brief_title":"Cabazitaxel in mCRPC Patients With AR-V7 Positive CTCs","source_id_and_acronym":"NCT02621190 - CARVE","lead_sponsor":"Erasmus Medical Center","biomarkers":" AR","pipe":" | ","alterations":" AR splice variant 7 • AR-V7 expression","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR splice variant 7 • AR-V7 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e abiraterone acetate • cabazitaxel"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 02/01/2019","primary_completion_date":" 02/01/2019","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2016-08-17"}]